NO20063784L - Fremgangsmate for a tilveiebringe et virusfritt antistoffpreparat - Google Patents

Fremgangsmate for a tilveiebringe et virusfritt antistoffpreparat

Info

Publication number
NO20063784L
NO20063784L NO20063784A NO20063784A NO20063784L NO 20063784 L NO20063784 L NO 20063784L NO 20063784 A NO20063784 A NO 20063784A NO 20063784 A NO20063784 A NO 20063784A NO 20063784 L NO20063784 L NO 20063784L
Authority
NO
Norway
Prior art keywords
approx
solution
virus
antibody preparation
antibodies
Prior art date
Application number
NO20063784A
Other languages
English (en)
Inventor
Andrea Buchacher
Juergen Romisch
Guenther Iberer
Original Assignee
Octapharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34910983&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20063784(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Octapharma Ag filed Critical Octapharma Ag
Publication of NO20063784L publication Critical patent/NO20063784L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0017—Filtration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0023—Heat

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Sammendrag En fremgangsmåte for fremstilling av et renset, virus inaktivert og virusfritt antistoffpreparat fra en startløsning omfattende antistoffer og forurensinger, fremgangsmåten omfatter trinnene av: 5 (a) justering av pH til startløsningen til ca. 4,6 til ca. 4,95 spesielt til ca. 4,8 til ca. 4,95 for å produsere en intermediat-løsning; (b) tilsette kaprylat- og/eller heptanoat-ioner til intermediat-løsningen og vedlikeholding av pH på ca. 4,6 til ca. 4,95 spesielt pH på ca. 4,8 til ca. 4,95, hvor et bunnfall dannes og antistoffene vesentlig blir 10 presentert i supernatanten; (c) inkubering av supernatant-løsningen under betingelser av kaprylatog/eller heptanoat-ionekonsentrasjon, tid, pH og temperatur valgfritt konsentrering og diafiltrating av filtrat-løsningen før pH-justering; (d) påføre den filtrerte løsningen på minst en anionbytter-resin og 15 valgfritt med to forskjellige anionbytter-resiner under betingelser som tillater binding av forurensninger til resinet mens ikke tillater signifikant binding av antistoffene til resinet, hvori et renset, virus inaktivert og virusfritt antistoffpreparat blir produsert.
NO20063784A 2004-02-27 2006-08-24 Fremgangsmate for a tilveiebringe et virusfritt antistoffpreparat NO20063784L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54810704P 2004-02-27 2004-02-27
PCT/EP2005/050812 WO2005082937A2 (en) 2004-02-27 2005-02-25 A method of providing a purified, virus safe antibody preparation

Publications (1)

Publication Number Publication Date
NO20063784L true NO20063784L (no) 2006-09-25

Family

ID=34910983

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063784A NO20063784L (no) 2004-02-27 2006-08-24 Fremgangsmate for a tilveiebringe et virusfritt antistoffpreparat

Country Status (18)

Country Link
US (1) US7553938B2 (no)
EP (2) EP2277915A1 (no)
JP (1) JP5042817B2 (no)
KR (1) KR101206788B1 (no)
CN (1) CN1922207B (no)
AU (1) AU2005217148B2 (no)
BR (1) BRPI0508096B8 (no)
CA (1) CA2557229C (no)
DK (1) DK1718675T3 (no)
ES (1) ES2407380T5 (no)
IL (1) IL177541A (no)
NO (1) NO20063784L (no)
PL (1) PL1718675T3 (no)
PT (1) PT1718675E (no)
RU (1) RU2337109C2 (no)
UA (1) UA87836C2 (no)
WO (1) WO2005082937A2 (no)
ZA (1) ZA200607119B (no)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2069387A4 (en) * 2006-06-14 2011-02-02 Glaxosmithkline Llc METHODS OF PURIFYING ANTIBODIES USING HYDROXYAPATITE CERAMIC
JP5505853B2 (ja) 2007-02-13 2014-05-28 味の素株式会社 微酸性アルギニンを添加剤とするウイルス不活化法
WO2009118331A1 (en) * 2008-03-28 2009-10-01 Research Foundation For Medical Devices Method of viral inactivation of biological fluids by solvent/detergent-treatment
EP3708581A3 (en) 2009-05-27 2021-10-20 Takeda Pharmaceutical Company Limited A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
EP2519537A4 (en) * 2009-12-29 2013-07-10 Reddys Lab Ltd Dr CLEANING PROTEINS
GB201006753D0 (en) * 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US8796430B2 (en) 2010-05-26 2014-08-05 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
EP2399613A1 (en) * 2010-06-22 2011-12-28 Research Foundation For Medical Devices Fractionation of plasma using caprylic acid
JP6023715B2 (ja) * 2010-10-11 2016-11-09 アッヴィ・バハマズ・リミテッド タンパク質の精製方法
KR20130128382A (ko) 2010-10-13 2013-11-26 옥타파마 아게 보체 인자 ｈ의 정제 방법
EP2670429B1 (en) 2011-02-04 2018-04-04 Octapharma AG Method for inactivation/removal of coagulation factors by precipitation
FR2977893B1 (fr) * 2011-07-11 2015-02-20 Lab Francais Du Fractionnement Procede de preparation d'un concentre d'immunoglobulines polyvalentes
CN102286099B (zh) * 2011-08-05 2014-04-09 深圳市卫光生物制品股份有限公司 静注巨细胞病毒人免疫球蛋白及其制备方法
TWI629283B (zh) 2012-02-23 2018-07-11 巴克斯歐塔公司 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱
CN110343171A (zh) 2012-02-29 2019-10-18 百深公司 周围神经的IgG刺激髓鞘再生
SG11201407809QA (en) 2012-05-31 2014-12-30 Agency Science Tech & Res Chromatographic purification of immunoglobulin g preparations with particles having multimodal functionalities
CN102757496B (zh) * 2012-06-07 2014-06-18 山东泉港药业有限公司 一种抗vegf抗体片段的纯化制备方法
EP2864346B1 (en) * 2012-06-21 2018-10-17 Synthon Biopharmaceuticals B.V. Method of purifying an antibody
AU2013205138B2 (en) 2012-08-09 2015-06-25 Grifols, S.A. Caprylate Viral Deactivation
KR20150123796A (ko) * 2013-02-28 2015-11-04 에이전시 포 사이언스, 테크놀로지 앤드 리서치 크로마틴 결핍 세포 배양 수확물로부터의 항체들의 크로마토그래프 정제
BR112015021495A2 (pt) 2013-03-08 2017-07-18 Genzyme Corp fabricação contínua integrada de substâncias de droga de proteína terapêutica
DK3680000T3 (da) * 2013-03-15 2024-04-02 Glaxosmithkline Ip Dev Ltd Fremgangsmåder til oprensning af antistoffer
US20160287693A1 (en) 2013-11-15 2016-10-06 Novartis Ag Removal of residual cell culture impurities
RU2561596C2 (ru) * 2013-12-18 2015-08-27 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Способ приготовления вирусинактивированных растворов иммуноглобулинов с низким остаточным содержанием каприловой кислоты
TWI671312B (zh) 2014-01-17 2019-09-11 美商健臻公司 無菌層析法及製法
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
CN106164086A (zh) * 2014-02-27 2016-11-23 新加坡科技研究局 抗体纯化方法
EP3118210B1 (en) * 2014-03-11 2019-11-13 Green Cross Holdings Corporation Method for purifying immunoglobulin
ES2857582T3 (es) * 2014-04-30 2021-09-29 Novo Nordisk As Métodos para la purificación de proteínas mediante el uso de ácido caprílico
WO2015195453A2 (en) 2014-06-16 2015-12-23 Emd Millipore Corporation Methods for increasing the capacity of flow-through processes
US10207225B2 (en) 2014-06-16 2019-02-19 Emd Millipore Corporation Single-pass filtration systems and processes
WO2015200691A1 (en) 2014-06-25 2015-12-30 Emd Millipore Corporation Compact spiral-wound filter elements, modules and systems
EP3185996B1 (en) 2014-08-29 2022-06-15 EMD Millipore Corporation Single pass tangential flow filtration systems and tangential flow filtration systems with recirculation of retentate
SG11201508665QA (en) 2014-08-29 2016-03-30 Emd Millipore Corp Processes For Filtering Liquids Using Single Pass Tangential Flow Filtration Systems AndTangential Flow Filtration Systems With Recirculation of Retentate
PL3135687T3 (pl) 2015-08-31 2019-09-30 Instituto Grifols, S.A. Sposób wytwarzania immunoglobulin
EP3254671B1 (en) 2016-06-10 2019-11-13 Octapharma AG High concentration immunoglobulin composition for pharmaceutical application
IT201600079328A1 (it) * 2016-07-28 2018-01-28 Altergon Sa Metodo migliorato per la decontaminazione di materiale biologico mediante partizione e inattivazione
CN109689675A (zh) 2016-09-07 2019-04-26 葛兰素史密斯克莱知识产权发展有限公司 纯化抗体的方法
RU2708394C2 (ru) * 2016-09-26 2019-12-06 Институто Грифольс,С.А. Способ получения иммуноглобулинов
JP6370853B2 (ja) * 2016-09-26 2018-08-08 インスティトゥト グリフォルス，ソシエダ アノニマ 免疫グロブリンの調製方法
US11369703B2 (en) 2018-08-31 2022-06-28 Genzyme Corporation Sterile chromatography resin and use thereof in manufacturing processes
CN110590931B (zh) * 2019-09-05 2023-04-07 江苏康禾生物制药有限公司 去除和/或灭活重组人血小板生成因子原液中病毒的方法
CN110627892B (zh) * 2019-09-05 2023-04-14 江苏康禾生物制药有限公司 一种重组人血小板生成因子原液的制备方法
EP4126930A1 (en) 2020-03-31 2023-02-08 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation from c-1 inhibitor depleted plasma
CN111991571B (zh) * 2020-08-12 2022-04-05 湖州师范学院 一种柱上低pH病毒灭活的方法
CA3203540A1 (en) * 2020-12-28 2022-07-07 Eugene ZURLO Systems and methods for process scale isolation of immunoglobulin g
AU2022281187A1 (en) * 2021-05-26 2023-12-07 Csl Behring Ag Plasma fractionation by continuous extraction
BE1029863B1 (nl) * 2022-05-10 2023-05-12 Prothya Biosolutions Belgium WERKWIJZEN VOOR HET PRODUCEREN VAN IMMUNOGLOBULINE G (IgG) PREPARATEN EN/OF OPLOSSINGEN

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1201063A (en) 1982-07-20 1986-02-25 Winnipeg Rh Institute Inc., (The) Process for preparing purified immune globulin (igg)
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
GB8807380D0 (en) 1988-03-29 1988-05-05 Gunn A Blood processing apparatus
US4939176A (en) 1988-12-20 1990-07-03 Miles Inc. Viral inactivation process
DE4125625C2 (de) 1991-08-02 1999-12-02 Octapharma Ag Glarus Verfahren zur Herstellung von virusinaktivierten Immunglobulinlösungen
EP1842561A1 (fr) 1995-07-14 2007-10-10 CAF - DCF cvba - scrl Procédé et installation d'inactivation UV de virus dans des produits sanguins
US5808011A (en) 1996-07-01 1998-09-15 Biopure Corporation Method for chromatographic removal of prions
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
US5886154A (en) * 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
US6281336B1 (en) * 1998-06-09 2001-08-28 Statens Serum Institut Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
CN1151174C (zh) * 1998-12-21 2004-05-26 蒋盘宏 抗人淋巴细胞球蛋白制备方法
EP1709077A1 (en) * 2004-01-30 2006-10-11 Suomen Punainen Risti Veripalvelu Process for the manufacture of virus safe immunoglobulin

Also Published As

Publication number Publication date
DK1718675T3 (da) 2013-07-15
EP1718675A2 (en) 2006-11-08
RU2006134285A (ru) 2008-04-10
CN1922207A (zh) 2007-02-28
EP1718675B2 (en) 2017-01-25
BRPI0508096B1 (pt) 2019-04-02
ZA200607119B (en) 2007-04-25
JP2007533660A (ja) 2007-11-22
US20070173638A1 (en) 2007-07-26
WO2005082937A3 (en) 2005-11-17
IL177541A (en) 2014-09-30
PL1718675T3 (pl) 2013-09-30
ES2407380T3 (es) 2013-06-12
IL177541A0 (en) 2006-12-10
BRPI0508096B8 (pt) 2021-05-25
UA87836C2 (ru) 2009-08-25
JP5042817B2 (ja) 2012-10-03
ES2407380T5 (es) 2017-07-07
CN1922207B (zh) 2012-06-06
RU2337109C2 (ru) 2008-10-27
WO2005082937A2 (en) 2005-09-09
BRPI0508096A (pt) 2007-07-17
PT1718675E (pt) 2013-05-21
CA2557229A1 (en) 2005-09-09
AU2005217148A1 (en) 2005-09-09
KR101206788B1 (ko) 2012-11-30
EP1718675B1 (en) 2013-04-10
CA2557229C (en) 2012-07-10
KR20060131920A (ko) 2006-12-20
US7553938B2 (en) 2009-06-30
AU2005217148B2 (en) 2011-09-08
EP2277915A1 (en) 2011-01-26

Similar Documents

Publication Publication Date Title
NO20063784L (no) Fremgangsmate for a tilveiebringe et virusfritt antistoffpreparat
AR121861A2 (es) MÉTODO PARA PREPARAR UNA COMPOSICIÓN DE IgG ENRIQUECIDA A PARTIR DE PLASMA
CY1120499T1 (el) Καθαρισμος βακτηριακων καψικων πολυσακχαριδιων
EA200801439A1 (ru) Способы производства частиц оксида титана, частицы и вещества, полученные этими способами
DK0831812T3 (da) Fremgangsmåder og præparater til stimulering af neuritvækst
JP2007533660A5 (no)
DK1409539T3 (da) Fremgangsmåde til fremstilling af en proteinholdig fraktion beriget med beta-TGF i aktiveret form, en proteinfraktion og terapeutiske anvendelser
EA200700135A1 (ru) Способ производства наночастиц оксида железа
TW200612989A (en) Process for concentration of antibodies and therapeutic products thereof
ATE239448T1 (de) Verfahren zur herstellung von wässrigen formulierungen für ophthalmische verwendung
RU2011137030A (ru) Способы очистки малых модулярных иммунофармацевтических белков
NO20012158L (no) Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav
DK1151007T3 (da) Fremgangsmåde til fremstilling af et præparat baseret på fibrinogen og fibronectin samt proteinsammensætninger fremstillet derved
DK1718673T3 (da) Fremgangsmåde til rensning af albumin omfattende et nanofiltreringstrin, oplösning og sammensætning til terapeutisk anvendelse, som indeholder det
DE69225888D1 (de) Katalase, ihre herstellung und verwendung
NO20044606L (no) Polymorfe former av lansoprazol og fremgangsmater for fremstilling derav
SG10201803982TA (en) Antibodies and processes for preparing the same
DK0550509T3 (da) Fremgangsmåde til fremstilling af rensede glycolipider ved membranseparationsmetoden
DK1513800T3 (da) Benzoylureido-kanelsyrederivater, fremgangsmåde til deres anvendelse
EE200500012A (et) Peptiid-pähine passiivne immunoteraapia ateroskleroosi raviks
EP1896588A4 (en) NOVEL Aβ BINDING PROTEIN, ITS PEPTIDE DERIVATIVES AND USES THEREOF
DK1165615T3 (da) Monoklonale antistoffer mod humant protein Mcm3, proces til deres fremstilling af deres anvendelse
DK0473270T3 (da) Fremgangsmåde til fremstilling af et transparent, indstillet mælkevalleprotein og et indstillet mælkevalleproteinprodukt
DK1165489T3 (da) Fremgangsmåde til fremstilling af gabapentin
MY136360A (en) Cyclohexane derivatives and methods for their preparation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application